Paclitaxel, carboplatin and gemcitabine combination as induction chemotherapyfor stage IIIA N2 bulky non-small cell lung cancer

Antonio Russo, Franco Marletta, Alessandro Pappalardo, Enrico Potenza, Roberto Bordonaro, Dario Giuffrida, Sergio Castorina, Bruno Vincenzi, Salvino Saita, Giorgio Carmelo Giannitto, Giuseppe La Venia

Risultato della ricerca: Articlepeer review

6 Citazioni (Scopus)

Abstract

Background: Induct ion chemotherapy followed by surgical resection or definitive radiotherapy for patients affected by stage IIIA N2 bulky non-small cell lung cancer (NSCLC) has been investigated in several trials. Patients and Methods: In this present study, 52 patients with stage IIIA N2 bulky NSCLC with cytologically or histologically confirmed mediastinal lymph node involvement received paclitaxel 175 mg/mq on day 1, carboplatin AUC 5 on day 1 and gemcitabine 1,000 mg/mq on day 1 and 8 every 3 weeks for three cycles as induction chemotherapy. Results: Objective response (4 complete remission and 36 partial remission) was achieved in 40/52 patients. No early or toxic deaths were observed. Twenty-two patients were surgically explored. Fifteen were excluded for resection for biopsy-proven residual tumour in mediastinal nodes. Complete surgical resection was performed in 15 patients with confirmed pathological downstaging. Pathological complete response was achieved in 4 patients. No surgery-related mortality or significant morbidity was reported. Adjuvant radiotherapy was delivered in 15 patients, and 30 patients received definitive radiotherapy. Conclusion: In the present study, the combination of paclitaxel, carboplatin and gemcitabine has been a safe and active regimen in poor-prognosis stage IIIA N2 bulky NSCLC.
Lingua originaleEnglish
pagine (da-a)295-300
Numero di pagine6
RivistaModern Pathology
Volume69
Stato di pubblicazionePublished - 2005

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Entra nei temi di ricerca di 'Paclitaxel, carboplatin and gemcitabine combination as induction chemotherapyfor stage IIIA N2 bulky non-small cell lung cancer'. Insieme formano una fingerprint unica.

Cita questo